

April 29, 2009

## Rheumatology Snapshot: Rheumatoid Arthritis



Event: Annual Congress of the European League Against Rheu-



## Rheumatoid Arthritis Drugs with USD +500m Peak Sales

**Amgen** (NASDAQ:AMGN)/**Wyeth** (NYSE:WYE): Enbrel- human tumor necrosis factor receptor fusion protein

- [Abbott, JNJ, Amgen: RA drugs will not be affected by comparative effectiveness studies without large scale clinical trials, physicians say \(Pharmawire\)](#)
- [Wyeth's COMET trial for rheumatoid arthritis while reassuring does not provide physicians with enough new data to generate excitement \(Pharmawire\)](#)

**JNJ** (NYSE:JNJ)/ **Schering-Plough Corporation** (NYSE:SGP): Remicade- chimeric anti-TNF $\alpha$  antibody

- [Elan's Tysabri PML risk still worries physicians, may affect other immunosuppressants like Enbrel, Humira, Remicade - analysis \(Pharmawire\)](#)

**Abbott** (NYSE:ABT): Humira- humanized anti-TNF antibody

- [Abbott may have several lines of defense against Bayer in Humira infringement case, attorneys say \(Pharmawire\)](#)

**Bristol-Myers-Squibb** (NYSE:BMJ): Orenicia-T-cell co-stimulator

**Merck & Co** (NYSE:MRK): Arcoxia-COX-2 selective inhibitor

**Genentech** (NYSE:DNA)/ **Roche Holding Ltd** (VTX:ROG): Rituxan-anti CD20 monoclonal antibody

**Pfizer** (NYSE:PFE): Celebrex-COX-2 selective inhibitor



## Rheumatoid Arthritis Drugs in Development

**Amgen** (NASDAQ:AMGN): denosumab- Anti CD20 monoclonal antibody

- [Amgen's denosumab likely to receive FDA approval, but physicians have concerns about its long-term effects \(Pharmawire\)](#)
- [Amgen: Denosumab overuse could lead to atypical fractures; offers advantages over bisphosphonates, physicians say \(Pharmawire\)](#)
- [Amgen must price denosumab similar to peers to compete in the osteoporosis market, physicians speculate \(Pharmawire\)](#)

**UCB** (EBR:UCB): Cimzia- Humanized anti-TNF $\alpha$  monoclonal antibody

- [UCB will release efficacy and safety data for Cimzia as monotherapy in RA \(Pharmawire\)](#)
- [UCB's Cimzia: rheumatologists question whether PEGylated Fc-free antibody concretely increases benefits over full antibody anti-TNFs \(Pharmawire\)](#)
- [UCB's Cimzia: pricing may play a part in patient adoption for Rheumatoid Arthritis in Europe, rheumatologists suggest \(Pharmawire\)](#)

**Roche Holding Ltd** (VTX:ROG): Actemra-Humanized monoclonal antibody against IL-6R

- [Roche's Actemra will likely be approved in the US, but patients may have to be monitored for liver enzyme elevations, physicians say \(Pharmawire\)](#)
- [Roche: Actemra's mechanism of action well received by rheumatologists; efficacy and safety data makes approval likely in EU, experts say \(Pharmawire\)](#)

**JNJ** (NYSE:JNJ): Simponi- Human monoclonal anti-TNF antibody

- [JNJ's Simponi monthly dosing schedule not seen as advantage, physicians say \(Pharmawire\)](#)
- [JNJ must keep golimumab price similar to other TNF-inhibitors in order to avoid reimbursement issues, physicians say \(Pharmawire\)](#)
- [Johnson & Johnson's golimumab produces fewer neutralizing antibodies but should not be the drug's only selling point, physicians say UPDATE 11/07/08 \(Pharmawire\)](#)

**Novartis** (VTX:NOVN): canakinumab- Long acting IL-1 $\beta$  monoclonal antibody

- [IL-1 drugs for rheumatoid arthritis face skepticism due to recent Amgen failure, but may find use in other niche inflammatory diseases - analysis \(Pharmawire\)](#)

**Trubion Pharma** (NASDAQ:TRBN)/ **Wyeth** (NYSE:WYE): TRU-015- Anti CD20 monoclonal antibody

- [Wyeth and Trubion's TRU-015 part of ongoing trend of higher bar being established in RA with ACR 50 primary endpoint, physicians say \(Pharmawire\)](#)
- [Wyeth/Trubion's TRU-015 shows similar efficacy to Rituxan in Phase II studies in salvage setting for RA; but data still premature, physicians say \(Pharmawire\)](#)

**Pfizer** (NYSE:PFE): CP-690550- JAK-3 inhibitor

- [Incyte's INCB18424 and Pfizer's CP-690550 for the treatment of rheumatoid arthritis have similar effects despite targeting different kinases - physicians \(Pharmawire\)](#)
- [Incyte's INCB18424 and Pfizer's CP-690550 likely to attract patients due to oral formulation and attractive pricing, physicians say \(Pharmawire\)](#)

**GlaxoSmithKline** (LON:GSK)/**Genmab** (CPH:GEN): Arzerra- anti CD20 monoclonal antibody

- [GSK and Genmab's Arzerra will likely face a limited market and reimbursement difficulties, if not priced on par with Genentech's Rituxan, sources say \(Pharmawire\)](#)

**Genentech** (NYSE:DNA)/ **Roche Holding Ltd** (VTX:ROG): ocrelizumab- anti CD20 monoclonal antibody

**Pozen** (NASDAQ: POZN)/**AstraZeneca** (LON:AZN): PN 400- non-steroidal anti-inflammatory and proton pump inhibitor

